Evidence map›Paper›PMID 37569654›Full record

ArticleInternational journal of molecular sciences2023

Benzenesulfonamide Analogs: Synthesis, Anti-GBM Activity and Pharmacoprofiling.

Akshaya Murugesan, Saravanan Konda Mani, Ramesh Thiyagarajan, Suresh Palanivel, Atash V Gurbanov, Fedor I Zubkov, Meenakshisundaram Kandhavelu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 6 countries.

Akshaya MurugesanDepartment of Biotechnology, Lady Doak College, Madurai Kamaraj University, Thallakulam, Madurai 625002, India.
Saravanan Konda ManiDepartment of Biotechnology, Bharath Institute of Higher Education & Research, Chennai 600073, India.ORCID 0000-0002-5541-234X
Ramesh ThiyagarajanDepartment of Basic Medical Sciences, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Suresh PalanivelMolecular Signaling Group, Faculty of Medicine and Health Technology, Tampere University and BioMediTech, P.O. Box 553, 33101 Tampere, Finland.
Atash V GurbanovCentro de Química Estrutural, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal.ORCID 0000-0003-1415-8012
Fedor I ZubkovOrganic Chemistry Department, Faculty of Science, RUDN University, 6 Miklukho-Maklaya St., 117198 Moscow, Russia.ORCID 0000-0002-0289-0831
Meenakshisundaram KandhaveluMolecular Signaling Group, Faculty of Medicine and Health Technology, Tampere University and BioMediTech, P.O. Box 553, 33101 Tampere, Finland.
Tampere University · FIBharath University · INMadurai Kamaraj University · INPeoples' Friendship University of Russia · RUPrince Sattam Bin Abdulaziz University · SAUniversity of Lisbon · PT

Funding

Fundação para a Ciência e Tecnologia UIDB/00100/2020 and UIDP/00100/2020Instituto Superior Técnico DL 57/2016, L 57/2017
6 · The paper itself

Abstract

The tropomyosin receptor kinase A (TrkA) family of receptor tyrosine kinases (RTKs) emerge as a potential target for glioblastoma (GBM) treatment. Benzenesulfonamide analogs were identified as kinase inhibitors possessing promising anticancer properties. In the present work, four known and two novel benzenesulfonamide derivatives were synthesized, and their inhibitory activities in TrkA overexpressing cells, U87 and MEF cells were investigated. The cytotoxic effect of benzenesulfonamide derivatives and cisplatin was determined using trypan blue exclusion assays. The mode of interaction of benzenesulfonamides with TrkA was predicted by docking and structural analysis. ADMET profiling was also performed for all compounds to calculate the drug likeness property. Appropriate QSAR models were developed for studying structure-activity relationships. Compound 4-[2-(4,4-dimethyl-2,6-dioxocyclohexylidene)hydrazinyl]-

Indexed as

Antineoplastic AgentsGlioblastomaAutoantibodiesBenzenesulfonamidesCell ProliferationCisplatinDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity Relationshipantiglomerular basement membrane antibodyAntineoplastic AgentsAutoantibodiesBenzenesulfonamidesCisplatinbenzenesulfonamide analogscell deathglioblastomapharmacokineticsRTK inhibitor

Identifiers

PMID37569654
PMCPMC10418358
OpenAlexW4385445511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.